This digital era is all about catching up with trends, TikToks and reels, but at the cost of what? Many believe all of this happens at the cost of one's health and mental well-being. As a result, the grades of students, especially in high school, when they are exposed to social media the most, start to drop. However, a study based on the University of Birmingham's findings, peer-revied and published by the Lancet's journal for European health policy compared 1,277 students and the rules their 30 different secondary schools had for smartphone use at break and lunchtimes.` The study found something else, contrary to the popular belief.

What Did The Study Find?

The study found that banning phones in school is not linked to pupils getting higher grades or having a better mental wellbeing. The study found that a student's sleep, classroom behavior, exercise or how long they spend on their phones did not seem much different for schools with phone bans versus schools without it.

However, the study did find that spending longer time in social media or on smartphones in general may be linked to such measures. This was the first study in the world that looked at school phone rules along with the children's health and education.

In an interview to the BBC, Dr Victoria Goodyear, study's lead author said, that the findings are not against smartphone bans in school, but, a suggestion that bans in isolation are not enough to tackle the negative impacts.

The focus must be on reducing how much time the student spends on their phone, which cannot just be supervised in school.

How Was The Study Conducted?

The schools were chosen from a sample of 1,341 mainstream state schools in England. Among these the behavior of student form schools that banned the smartphones versus those who did not ban it were studied to find out that schools restricting smartphone use did not seem to see the intended improvements on health, wellbeing and focus of the student, as one would have wished to.

The study also used the internationally recognized Warwick-Edinburg Mental Well-Being Scale, a measure of mental well-being focusing entirely on positive aspects. It is a 14-item scale with 5 response categories. This method was used to determine the wellbeing of the children who participated in the research. It further looked at students' anxiety and depression levels.

It also asked from teachers about whether their students were on target, below target or above target in English and maths.

What Do The Students Feel?

When asked students, they said that the smartphone ban forces you to hang out and chat with your friends and some of them think in lower school, it has helped them spend less time scrolling social media and making lots of friends.

Experts point out that the important part is to help students learn to use their phone in a safe and controlled space. This way, phone-related issues, especially distraction, its impact on your mental health, will be much less. The answer is not ban, but the use of the smartphone in a controlled environment, so students learn to value the "freedom" they have been given to use them at break and lunch.

The risk of hantavirus spreading is generally considered low, as repeatedly stated by the World Health Organization (WHO) and other global health agencies, after the recent outbreak on the MV Hondius cruise ship. However, a shocking peer-reviewed study has found that the Andes strain of the rat-borne virus can persist in human semen for up to six years.

More concerning is the possibility that the virus could potentially be transmitted sexually even after a person has recovered, according to the 2023 study published in the journal Viruses.

The research, conducted by Swiss scientists at Spiez Laboratory, suggests that hantavirus may survive in the male reproductive tract like viruses such as Ebola.

What Did The Study Find?

The research team, which included scientists from the University of Bern and the University of Lausanne, investigated a 55-year-old man who had contracted the Andes strain of hantavirus in South America six years earlier.

The researchers discovered that although the virus was no longer detectable in the man’s blood, urine, or respiratory tract, it was still present in his semen 71 months later.

"Viral RNA remained primarily detectable intracellularly in semen samples throughout the complete study period of almost six years," the 2023 study stated,

“Taken together, our results show that the Andes virus has the potential for sexual transmission,” it added. However, so far no confirmed case of such transmission has yet been documented.

Also read: Hantavirus Outbreak: Critically Ill French Patient On Artificial Lung Support

Andes Virus: Male Testes Hidden ‘Reservoirs’?

Hantavirus is not the first virus found to persist in the male reproductive system. According to the study, viruses such as Ebola and Zika are also known to evade the immune system by remaining hidden in the testes for extended periods.

A 2021 Ebola outbreak in Guinea, which resulted in 23 cases and 12 deaths, was later linked to a survivor of the 2014–2016 West Africa epidemic who reportedly transmitted the virus sexually years after recovery.

The testes are considered a biological “safe harbour” for at least 27 infectious diseases, enabling certain pathogens to remain hidden in the body and potentially spread years after a patient has recovered.

Because sperm cells are essential for reproduction, they are shielded from the body’s immune response. However, this immune protection can also create an environment where viruses are able to survive and persist for long periods.

Safe-Sex Guidance For Hantavirus-Infected Individuals

Analysts at Airfinity, a company that tracks global health risks, recommend that male patients should receive “extensive safe-sex guidance beyond the [42-day] quarantine”, the Telegraph reported

The guidance should be “analogous to the World Health Organization’s (WHO) Ebola survivor semen-monitoring protocols,” it added.

The WHO protocols recommend that the semen of male Ebola survivors should be tested every three months and should not be considered virus-free until two consecutive negative test results are obtained.

Until cleared, they should “abstain from all types of sex” or “use condoms consistently and correctly.”

They should also wash themselves “thoroughly” with soap and water after any contact with semen – including after masturbation, according to the guidance.

Hantavirus on MV Hondius

According to the World Health Organization (WHO), 11 people have been affected by the rat-borne virus so far, of whom three have died.

A Dutch couple is believed to have been first exposed to the virus while visiting a birdwatching site in Argentina.

The WHO has confirmed that the Andes strain of hantavirus — the only strain known to spread from person to person — is behind the outbreak.

While all passengers onboard the cruise have been taken care of by health authorities, the virus' long incubation period is a serious risk factor. Which means that even those asymptomatic can turn infectious 6-8 weeks later.

While GLP-1 weight-loss drugs such as Wegovy and Mounjaro have helped patients lose weight, a major concern has been weight regain once the therapy is stopped. Now, a new study by US scientists suggests that a daily pill may help prevent that rebound weight gain.

According to a clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian, switching to the once-daily orforglipron pill may not only help maintain weight loss but also preserve cardiometabolic benefits.

Orforglipron is US drugmaker Eli Lilly’s first oral pill for weight loss, marketed as Foundayo. In April, it received approval from the US Food and Drug Administration (FDA).

Weight Loss With Daily Pill Orforglipron

In the Eli Lilly-funded trial, published in the journal Nature Medicine, researchers found that patients in the Phase 3b clinical trial maintained around 75–80 per cent of their weight loss. They also experienced several additional health benefits, including:

• Reduced waist circumference
• Improved blood pressure
• Better blood sugar control
• Lower triglyceride levels
• Improved cholesterol levels

The Clinical Trial

The ATTAIN-MAINTAIN trial enrolled patients who had already achieved substantial weight loss that later plateaued while taking weekly injectable GLP-1 drugs during the SURMOUNT-5 trial.

The study randomized:

• 205 patients taking tirzepatide
• 171 patients taking semaglutide

The results showed that patients switching from tirzepatide to orforglipron maintained an average of 74.7 per cent of their body weight reduction, compared with 49.2 per cent in the placebo group.

Meanwhile, patients who switched from semaglutide to orforglipron maintained 79.3 per cent of their body weight reduction, compared with 37.6 per cent in the placebo arm.

Over the 52-week trial period, participants treated with orforglipron gained:

• An average of 5 kg (11 lbs) in the tirzepatide group
• An average of 1 kg (2.2 lbs) in the semaglutide group

How The Daily Pill Orforglipron Works

Eli Lilly licensed orforglipron, the active ingredient in Foundayo, from a Japanese pharmaceutical company in 2018.

Like injectable GLP-1 drugs, Orforglipron is available in six doses ranging from 0.8 mg to 17.2 mg. Patients typically begin at the lowest dose and gradually increase under medical supervision.

Also read: Donald Trump Will Have Fourth Medical Checkup In May, Says White House

Unlike some oral GLP-1 drugs, people taking orforglipron do not need to restrict food or drink intake after taking the pill. Researchers say the small molecule is absorbed quickly into the bloodstream and reaches target tissues efficiently.

Orforglipron: Side Effects And Safety Concerns

Foundayo is not approved for use in children and carries warnings about potential thyroid tumours, including thyroid cancer.

The drugmaker advises patients to watch for symptoms such as:

• Lump or swelling in the neck
• Hoarseness
• Trouble swallowing
• Shortness of breath

• Nausea
• Constipation
• Diarrhoea
• Vomiting
• Indigestion
• Stomach pain
• Headache
• Swollen belly
• Fatigue
• Belching
• Heartburn
• Gas
• Hair loss.

In a major development for cancer care in India, Swiss pharmaceutical major Roche Pharma has launched Tecentriq SC, the country’s first subcutaneous (under-the-skin) immunotherapy for lung cancer that can be administered in approximately seven minutes.

While conventional intravenous (IV) infusions can take hours, Tecentriq SC can significantly improve the cancer treatment experience by reducing treatment time by nearly 80 per cent.

The seven-minute injectable immunotherapy has the potential to:

• Treat up to five patients in the time taken to treat one patient through intravenous infusion
• Help optimise healthcare resources
• Lower indirect treatment costs
• Minimise the need for patients to travel long distances
• Reduce the amount of time caregivers spend in hospitals

“With Tecentriq SC, we are bringing an innovation that meaningfully reduces treatment time while maintaining the established efficacy and safety profile of Tecentriq. We believe such advances can play an important role in enabling more patient-centric and future-ready cancer care delivery in India,” said Roche Pharma India Chief Medical Officer Dr Sivabalan Sivanesan, in a statement.

What Is Tecentriq SC? What's The Cost In India?

Tecentriq SC is the first and only PD-(L)1 inhibitor globally with both intravenous (IV) and subcutaneous (SC) formulations across multiple cancers.

First approved by the UK MHRA in 2023 and subsequently by the USFDA in 2024, Tecentriq SC is now approved in more than 85 countries, with over 10,000 patients benefitting globally.

In India, Tecentriq SC is currently approved by the DCGI for adjuvant and metastatic non-small cell lung cancer (NSCLC). NSCLC is the most common form, making up about 80–85% of all cases.

According to Sivanesan, the drug is priced at about "Rs 3.7 lakh per vial".

Also read: India Gets Its First Alzheimer’s Drug: Know All About Eli Lilly’s Lormalzi

How Does Tecentriq SC Work?

Tecentriq SC combines Tecentriq with Halozyme Therapeutics’ Enhanze drug delivery technology.

The technology uses recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that temporarily increases permeability in the subcutaneous space, enabling rapid dispersion and absorption of the medicine into the bloodstream, the company said.

How Tecentriq SC will Boost Cancer Care In India

The launch of Tecentriq SC also aligns with the broader shift toward decentralised cancer care in India. Shorter administration formats can free up hospital beds, healthcare staff time, and oncology resources at tertiary care centres, while helping shift care delivery to daycare centres and beyond traditional tertiary hospitals.

“India’s growing cancer burden requires us to rethink how cancer care is delivered. Innovations such as subcutaneous immunotherapy have the potential to simplify treatment administration, reduce pressure on hospital beds and support more decentralised models of care beyond large metro hospitals,” said Dr Amit Rauthan, Consultant and HOD of Medical Oncology at Manipal Hospital.

Read More: India Better Prepared For Hantavirus Outbreaks After COVID-19 Experience, Says Dr NK Ganguly | Exclusive

Tecentriq SC: Safety

Global studies have indicated strong patient preference for subcutaneous administration.

According to results from the IMscin002 study presented at the European Lung Cancer Congress (ELCC) 2024:

• Four out of five patients preferred Tecentriq SC over IV administration
• Patients cited less time in clinics, greater comfort, and lower emotional distress as key reasons for preference

Studies have also shown that subcutaneous administration is associated with less discomfort, pain, and irritation compared to IV administration.

In the IMscin001 study presented at ESMO 2023:

• 90 per cent of healthcare professionals agreed the SC formulation was easy to administer
• 75 per cent believed it could save time for healthcare teams.